Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine FoundationOne Monitor

Roche subsidiary Foundation Medicine has launched its FoundationOne Monitor test for research use in retrospective studies. The tissue-naive circulating tumor DNA monitoring assay is available for biopharmaceutical customers and uses the firm's ctDNA tumor fraction biomarker. The test quantifies ctDNA tumor fraction at each timepoint and offers molecular response insights to complement standard imaging in early-phase clinical research, the company said. It can also assess resistance to therapy across more than 300 genes. The assay is currently in development for clinical use.